GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Indrayani Biotech Ltd

Indrayani Biotech: BSE Approves Rights Issue Listing, Paid-up Capital at Rs. 53.25 Crore

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 06 Nov 2026, 02:39 PM IST  ·  BSE ID: 6fdcf7c9-2a27-4a98-b29b-2711927608d9
View Original BSE Filing (PDF)
💡
In Simple Terms
The stock exchange has approved the listing of new shares issued by Indrayani Biotech, following a rights issue.
🤖 AI Summary
  • BSE grants listing approval for Indrayani Biotech's rights issue.
  • 83,64,036 rights shares allotted post-rights issue.
  • Paid-up capital increased to Rs. 53,25,47,648.
  • Rs. 49.90 crore partly paid rights issue previously postponed.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Paid-up Capital
Rs. 53,25,47,648
Number of Rights Shares Allotted
83,64,036
Proposed Rights Issue Size (previously)
Rs. 49.90 crore
🏢 How This Affects the Company
📈
Business Impact
The approval formalizes the completion of the rights issue process, integrating the newly issued shares into the company's capital structure.
💰
Financial Impact
Paid-up capital has been raised to Rs. 53,25,47,648, reflecting the successful completion of the rights issue.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders regarding this listing approval.
👤
Who Is Affected
Shareholders who participated in the rights issue will now see their allotted shares listed on the exchange.
🔍
Management Signal
Management successfully navigated the regulatory process for the rights issue, indicating commitment to capital raising objectives.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Financial results for subsequent periods to assess capital utilization.
Updates on business performance post capital infusion.
Company disclosures on use of funds from rights issue.
MEDIUM RISK Past postponement of rights issue indicates potential execution challenges.
💡 Investor Takeaway
Indrayani Biotech's rights issue has received BSE listing approval. Paid-up capital now stands at Rs. 53,25,47,648 following the allotment of 83,64,036 rights shares.
⚖️ Strengths & Concerns

✅ Positives

  • BSE listing approval received for rights issue, a regulatory milestone.

⚠️ Concerns

  • Previous Rs. 49.90 crore partly paid rights issue was indefinitely postponed.
📅 Company Track Record
Indrayani Biotech's Rs. 49.90 crore partly paid rights issue was indefinitely postponed in June 2026 after initial approval in April 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the latest update on Indrayani Biotech's rights issue?
The BSE has granted listing approval for Indrayani Biotech's rights issue.
What is Indrayani Biotech's paid-up capital after the rights issue?
Indrayani Biotech's paid-up capital has increased to Rs. 53,25,47,648.
How many rights shares were allotted by Indrayani Biotech?
Indrayani Biotech allotted 83,64,036 rights shares.
Was there any prior development regarding Indrayani Biotech's rights issue?
Yes, a Rs. 49.90 crore partly paid rights issue was indefinitely postponed in June 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.